## Sentot Santoso

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/929971/publications.pdf

Version: 2024-02-01

92 papers 4,978 citations

36 h-index 95266 68 g-index

92 all docs 92 docs citations 92 times ranked 3873 citing authors

#	Article	IF	CITATIONS
1	348 CASES OF SUSPECTED NEONATAL ALLOIMMUNE THROMBOCYTOPENIA. Lancet, The, 1989, 333, 363-366.	13.7	592
2	The Junctional Adhesion Molecule 3 (JAM-3) on Human Platelets is a Counterreceptor for the Leukocyte Integrin Mac-1. Journal of Experimental Medicine, 2002, 196, 679-691.	8.5	392
3	The Neutrophil-specific Antigen CD177 Is a Counter-receptor for Platelet Endothelial Cell Adhesion Molecule-1 (CD31). Journal of Biological Chemistry, 2007, 282, 23603-23612.	3.4	205
4	The 2 Gene Coding Sequence T807/A873 of the Platelet Collagen Receptor Integrin 2β1 Might Be a Gene Risk Factor for the Development of Stroke in Younger Patients. Blood, 1999, 93, 3583-3586.	tic 1.4	186
5	Characterization of a New Alloantigen (SH) on the Human Neutrophil Fcγreceptor IIIb. Blood, 1997, 89, 1027-1034.	1.4	181
6	Heparin-Induced Thrombocytopenia: New Insights Into the Impact of the Fc $\hat{l}^3$ RIIa-R-H131 Polymorphism. Blood, 1998, 92, 1526-1531.	1.4	176
7	Selective release of circRNAs in plateletâ€derived extracellular vesicles. Journal of Extracellular Vesicles, 2018, 7, 1424473.	12.2	167
8	The Junctional Adhesion Molecule-C Promotes Neutrophil Transendothelial Migration in Vitro and in Vivo. Journal of Biological Chemistry, 2004, 279, 55602-55608.	3.4	160
9	Junctional adhesion molecule-C regulates vascular endothelial permeability by modulating VE-cadherin–mediated cell–cell contacts. Journal of Experimental Medicine, 2006, 203, 2703-2714.	8.5	154
10	Platelet alloantibodies in transfused patients. Transfusion, 2001, 41, 766-770.	1.6	135
11	Platelets Recruit Human Dendritic Cells Via Mac-1/JAM-C Interaction and Modulate Dendritic Cell Function In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1463-1470.	2.4	129
12	Autoantibodyâ€mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). European Journal of Haematology, 2012, 88, 167-174.	2,2	116
13	Junctional Adhesion Molecules (JAM)-B and -C Contribute to Leukocyte Extravasation to the Skin and Mediate Cutaneous Inflammation. Journal of Investigative Dermatology, 2005, 125, 969-976.	0.7	87
14	Molecular basis of the neutrophil glycoprotein NB1 (CD177) involved in the pathogenesis of immune neutropenias and transfusion reactions. European Journal of Immunology, 2001, 31, 1301-1309.	2.9	86
15	The role of junctional adhesion molecule  (JAM ) in oxidized LDLâ€mediated leukocyte recruitment. FASEB Journal, 2005, 19, 2078-2080.	0.5	85
16	Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1517-1524.	2.4	79
17	Complement Receptor Mac-1 Is an Adaptor for NB1 (CD177)-mediated PR3-ANCA Neutrophil Activation. Journal of Biological Chemistry, 2011, 286, 7070-7081.	3.4	77
18	Leukocyte trans-endothelial migration: JAMs add new pieces to the puzzle. Thrombosis and Haemostasis, 2003, 89, 13-17.	3.4	73

#	Article	IF	CITATIONS
19	The Homophilic Binding of Junctional Adhesion Molecule-C Mediates Tumor Cell-Endothelial Cell Interactions. Journal of Biological Chemistry, 2005, 280, 36326-36333.	3.4	71
20	Mechanisms of neutrophil transendothelial migration. Frontiers in Bioscience - Landmark, 2009, Volume, 1596.	3.0	66
21	A functional platelet fibrinogen receptor with a deletion in the cysteine-rich repeat region of the $\hat{l}^2$ 3 integrin: the Oea alloantigen in neonatal alloimmune thrombocytopenia. Blood, 2002, 99, 1205-1214.	1.4	65
22	A Novel Function of Junctional Adhesion Molecule-C in Mediating Melanoma Cell Metastasis. Cancer Research, 2011, 71, 4096-4105.	0.9	64
23	A Hydrophobic Patch on Proteinase 3, the Target of Autoantibodies in Wegener Granulomatosis, Mediates Membrane Binding via NB1 Receptors. Journal of Biological Chemistry, 2008, 283, 35976-35982.	3.4	63
24	Localization of the Br Polymorphism on a 144 bp Exon of the GPIa Gene and Its Application in Platelet DNA Typing. Thrombosis and Haemostasis, 1994, 71, 651-654.	3.4	58
25	A Point Mutation Thr799Met on the 2 Integrin Leads to the Formation of New Human Platelet Alloantigen Sita and Affects Collagen-Induced Aggregation. Blood, 1999, 94, 4103-4111.	1.4	55
26	High Molecular Weight Kininogen Regulates Platelet-Leukocyte Interactions by Bridging Mac-1 and Glycoprotein lb. Journal of Biological Chemistry, 2003, 278, 45375-45381.	3.4	55
27	Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion, 2005, 45, 353-358.	1.6	53
28	Anti–Human Neutrophil Antigen-3a Induced Transfusion-Related Acute Lung Injury in Mice by Direct Disturbance of Lung Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2538-2548.	2.4	53
29	Immunochemical characterization of the new platelet alloantigen system Bra/Brb. British Journal of Haematology, 1989, 72, 191-198.	2.5	52
30	Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion, 2004, 44, 1033-1040.	1.6	52
31	Human alloantibody anti-Mart interferes with Mac-1–dependent leukocyte adhesion. Blood, 2004, 104, 727-734.	1.4	49
32	The presence of messenger RNA for HLA class I in human platelets and its capability for protein biosynthesis. British Journal of Haematology, 1993, 84, 451-456.	2.5	48
33	The frequencies of human neutrophil alloantigens in the Chinese Han population of Guangzhou. Transfusion, 2011, 51, 1271-1277.	1.6	48
34	Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti–HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia. Blood, 2013, 122, 321-327.	1.4	47
35	The Impact of the Glycoprotein Ia Collagen Receptor Subunit A1648G Gene Polymorphism on Coronary Artery Disease and Acute Myocardial Infarction. Thrombosis and Haemostasis, 2000, 83, 392-396.	3.4	42
36	Junctional adhesion molecule (JAM) $\hat{a}\in B$ supports lymphocyte rolling and adhesion through interaction with $\hat{l}\pm 4\hat{l}^21$ integrin. Immunology, 2009, 128, 196-205.	4.4	39

#	Article	IF	Citations
37	Studies on CD36 deficiency in South China: Two cases demonstrating the clinical impact of anti-CD36 antibodies. Thrombosis and Haemostasis, 2013, 110, 1199-1206.	3.4	38
38	Lowâ€avidity antiâ€HPAâ€1a alloantibodies are capable of antigenâ€positive platelet destruction in the NOD/SCID mouse model of alloimmune thrombocytopenia. Transfusion, 2011, 51, 2455-2461.	1.6	36
39	Alloantibodies against lowâ€frequency human platelet antigens do not account for a significant proportion of cases of fetomaternal alloimmune thrombocytopenia: evidence from 1054 cases. Transfusion, 2009, 49, 2084-2089.	1.6	34
40	Choline Transporter-Like Protein-2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1616-1622.	2.4	33
41	Heterogeneity of HPA-3 alloantibodies: consequences for the diagnosis of alloimmune thrombocytopenic syndromes. Transfusion, 2008, 48, 463-472.	1.6	32
42	Single amino acid substitution in human platelet glycoprotein $lb\hat{l}^2$ is responsible for the formation of the platelet-specific alloantigen lya. Blood, 2000, 95, 1849-1855.	1.4	31
43	Lowâ€avidity HPAâ€1 a alloantibodies in severe neonatal alloimmune thrombocytopenia are detectable with surface plasmon resonance technology. Transfusion, 2009, 49, 943-952.	1.6	31
44	Alpha-1 Antitrypsin Inhibits ATP-Mediated Release of Interleukin- $1\hat{l}^2$ via CD36 and Nicotinic Acetylcholine Receptors. Frontiers in Immunology, 2018, 9, 877.	4.8	31
45	The Use of Allele-Specific Recombinant Fcl <sup>3</sup> Receptor IIIb Antigens for the Detection of Granulocyte Antibodies. Blood, 1999, 93, 357-362.	1.4	30
46	Monoclonal antibodies identify residues 199–216 of the integrin α2 vWFA domain as a functionally important region within α2β1. Biochemical Journal, 2000, 350, 485-493.	3.7	29
47	Functional heterogeneity of alloantibodies against the human platelet antigen (HPA)-1a. Thrombosis and Haemostasis, 2005, 94, 1224-1229.	3.4	29
48	Blockade of maternal antiâ€HPAâ€l a–mediated platelet clearance by an HPAâ€l a epitope–specific F(ab′) <sub>2</sub> in an in vivo mouse model of alloimmune thrombocytopenia. Transfusion, 2009, 49, 265-270.	1.6	28
49	Human platelet alloantigens. Transfusion and Apheresis Science, 2003, 28, 227-236.	1.0	27
50	Characterisation of patients with Glanzmann thrombasthenia and identification of 17 novel mutations. Thrombosis and Haemostasis, 2015, 113, 782-791.	3.4	27
51	A naturally occurring Leu33Val mutation in beta3-integrin impairs the HPA-1a epitope: the third allele of HPA-1. Transfusion, 2006, 46, 790-799.	1.6	26
52	HLAâ€DRB3*01:01 is a predictor of immunization against human platelet antigenâ€1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia. Transfusion, 2017, 57, 533-540.	1.6	26
53	PLATELET ALLOANTIGENSâ€MOLECULAR, GENETIC, AND CLINICAL ASPECTS. Vox Sanguinis, 1994, 67, 89-93.	1.5	25
54	Implication of transfected cell lines for the detection of alloantibodies against human neutrophil antigenâ€3. Transfusion, 2012, 52, 613-621.	1.6	25

#	Article	IF	CITATIONS
55	Human platelet alloantigens Bra/Brb are expressed on the very late activation antigen 2 (VLA-2) of T lymphocytes. Human Immunology, 1989, 25, 237-246.	2.4	23
56	Rapid detection of HPA-1 alloantibodies by platelet antigens immobilized onto microbeads. Transfusion, 2007, 47, 1363-1368.	1.6	20
57	PECAM-1-dependent heme oxygenase-1 regulation via an Nrf2-mediated pathway in endothelial cells. Thrombosis and Haemostasis, 2014, 111, 1077-1088.	3.4	20
58	Glycosylation of autoantibodies: Insights into the mechanisms of immune thrombocytopenia. Thrombosis and Haemostasis, 2013, 110, 1259-1266.	3.4	19
59	The implementation of surface plasmon resonance technique in monitoring pregnancies with expected fetal and neonatal alloimmune thrombocytopenia. Transfusion, 2013, 53, 2078-2085.	1.6	17
60	Successful management of a hydropic fetus with severe anemia and thrombocytopenia caused by anti-CD36 antibody. International Journal of Hematology, 2018, 107, 251-256.	1.6	16
61	Fetal/neonatal alloimmune thrombocytopenia due to antiâ€ <scp>CD36</scp> antibodies: antibody evaluations by <scp>CD36</scp> â€transfected cell lines. Transfusion, 2018, 58, 189-195.	1.6	15
62	The role of alloantibodies against human platelet antigenâ€15 in multiply platelet transfused patients. Transfusion, 2014, 54, 1093-1099.	1.6	14
63	Distribution of CD36 deficiency in different Chinese ethnic groups. Human Immunology, 2020, 81, 366-371.	2.4	14
64	Maternal antibodies against paternal class I human leukocyte antigens are not associated with foetal and neonatal alloimmune thrombocytopenia. British Journal of Haematology, 2020, 189, 751-759.	2.5	14
65	Rapid enzymeâ€linked immunosorbent assay for the detection of antibodies against human neutrophil antigens â€1a, â€1b, and â€1c. Transfusion, 2013, 53, 193-201.	1.6	13
66	A novel enzymeâ€inked immunosorbent assay method for the detection of human neutrophil antigenâ€2a antibodies. Transfusion, 2009, 49, 1819-1824.	1.6	12
67	The first case of alloantibody against human platelet antigenâ€15b in Japan: possible alloimmunization by a hydatidiform mole. Transfusion, 2010, 50, 1126-1130.	1.6	12
68	A point mutation in the EGF-4 domain of $\hat{l}^2$ 3 integrin is responsible for the formation of the Seca platelet alloantigen and affects receptor function. Thrombosis and Haemostasis, 2012, 107, 80-87.	3.4	12
69	Immunisation against αllbβ3 and αvβ3 in a type 1 variant of Glanzmann's thrombasthenia caused by a misse mutation Gly540Asp on β3. Thrombosis and Haemostasis, 2016, 116, 262-271.	ense 3.4	12
70	A beadâ€based assay in the workâ€up of suspected platelet alloimmunization. Transfusion, 2016, 56, 115-118.	1.6	12
71	Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies. Blood, 2019, 134, e1-e8.	1.4	12
72	A new platelet alloantigen, Swi <sup>a</sup> , located on glycoprotein la identified in a family with fetal and neonatal alloimmune thrombocytopenia. Transfusion, 2011, 51, 1745-1754.	1.6	11

#	Article	IF	CITATIONS
73	Heterogeneity of Platelet Alloantigens and Alloantibodies: New Insights into Structure and Function. Transfusion Medicine and Hemotherapy, 2006, 33, 244-253.	1.6	10
74	Hydrops fetalis associated with <scp>anti D36</scp> antibodies in fetal and neonatal alloimmune thrombocytopenia: Possible underlying mechanism. Transfusion Medicine, 2020, 30, 361-368.	1.1	10
75	Alloantibody against new platelet alloantigen (Lap <sup>a</sup> ) on glycoprotein IIb is responsible for a case of fetal and neonatal alloimmune thrombocytopenia. Transfusion, 2015, 55, 2920-2929.	1.6	9
76	Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model. Blood, 2021, 138, 1757-1767.	1.4	9
77	Current Anti-HPA-1a Standard Antibodies React with the $\hat{l}^2$ 3 Integrin Subunit but not with $\hat{l}$ ±IIb $\hat{l}^2$ 3 and $\hat{l}$ ±v $\hat{l}^2$ 3 Complexes. Thrombosis and Haemostasis, 2019, 119, 1807-1815.	3.4	8
78	The Neutrophil Specific CD177 Is a Novel Counter-Receptor for Endothelial PECAM-1 Blood, 2006, 108, 1635-1635.	1.4	8
79	Antiâ€human platelet antigenâ€5b antibodies and fetal and neonatal alloimmune thrombocytopenia; incidental association or cause and effect?. British Journal of Haematology, 2022, , .	2.5	8
80	Frequency of CD36 deficiency in Thais analyzed by quantification of CD36 on cell surfaces and in plasma. Transfusion, 2020, 60, 847-854.	1.6	7
81	Transcriptional induction of junctional adhesion molecule-C gene expression in activated T cells. Journal of Leukocyte Biology, 2009, 85, 796-803.	3.3	6
82	Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y12 Receptor and Aggregation. International Journal of Molecular Sciences, 2017, 18, 269.	4.1	6
83	Treatment of fetomaternal neonatal alloimmune thrombocytopenia with random platelets. Pediatric Blood and Cancer, 2008, 50, 1293-1294.	1.5	5
84	Naturally occurring point mutation <scp>Cys460Trp</scp> located in the <scp>lâ€EGF1</scp> domain of integrin β3 alters the binding of some <scp>antiâ€HPA</scp> â€ <scp>1a</scp> antibodies. Transfusion, 2020, 60, 2097-2107.	1.6	5
85	Lung Endothelial Injury Induced by HNA-3a Antibodies in TRALI. Blood, 2011, 118, 40-40.	1.4	5
86	Molecular and Functional Characterization of $Fc\hat{l}^3$ Receptor IIIb-Ligand Interaction: Implications for Neutrophil-Mediated Immune Mechanisms in Malaria. Infection and Immunity, 2018, 86, .	2.2	4
87	Neutrophil alloantigens and alloantibodies in different populations. ISBT Science Series, 2017, 12, 62-67.	1.1	3
88	Improvement of monoclonal antibody–immobilized granulocyte antigen assay for the detection of antiâ€HNAâ€1 alloantibodies. Transfusion, 2018, 58, 200-207.	1.6	3
89	Immunization against $\hat{l}$ ± IIb $\hat{l}^2$ 3 and $\hat{l}$ ± v $\hat{l}^2$ 3 in Glanzmann thrombasthenia patients carrying the French Gypsy mutation. Journal of Thrombosis and Haemostasis, 2021, 19, 255-261.	3.8	3
90	Rapid characterization of hybridomas producing monoclonal antibodies against platelet $\hat{l}^2$ 3 integrin using ELIspot. Platelets, 2016, 27, 758-763.	2.3	1

#	Article	IF	CITATIONS
91	The Role of Endothelial PECAM-1 Polymorphism (S536N) as Heterophilic Counter Receptor for Neutrophil Specific CD177 in Transendothelial Cell Migration Blood, 2008, 112, 1268-1268.	1.4	1
92	Identification of New CD177 Isoform in NB1 Deficient Individuals. Blood, 2008, 112, 1270-1270.	1.4	1